Startups
Rubato
Pacific Palisades, California, United States
U.S. digital health company developing biometrically personalized music-based interventions for dementia, mild cognitive impairment and related care needs. RUBATO combines machine learning, patient music preferences and wristband heart-rate and heart-rate-variability signals to adjust playlists and provide response information for caregivers and therapists in skilled nursing and rehabilitation settings. The company reports commercial deployment and clinical research collaborations; its current team includes co-founder and CEO Amit Sternberg, co-founder and Software Architect Noam Guy, and VP Sales & Clinical Success Mike Tully, alongside four named clinical advisors. Its funding relationships include 97212 Ventures and the Techstars Columbus spring2024 accelerator, with exact investment amounts and dates undisclosed in the primary sources reviewed. NIH/NIA awarded Rubato Inc. USD250,812 in fiscal2025 and USD243,043 in fiscal2026 for projectR41AG092161, a music-intervention study associated with Brown University; these are research awards, not equity rounds. The NIH recipient address is Pacific Palisades, California. ClinicalTrials.gov studyNCT06163378 has current status UNKNOWN, with last status verification in November2023 and no posted results; planned completion dates do not establish actual completion. Clinical use, research registration and publication are distinct from FDA approval or demonstrated treatment efficacy. Proposed expansion into oncology, PTSD or autism-related care remains company development intent.
Team
 Amit SternbergCo-Founder & CEO |
 Claudius ConradClinical Advisory Board Member |
 Frank AhmannClinical Advisory Board Member, Healthcare Consultancy |
 Indre ViskontasClinical Advisory Board Member, Cognitive Neuroscience |
 Kimberly LockwoodClinical Advisory Board Member, Physiological Measurement |
 Mike TullyVP Sales & Clinical Success |
 Noam GuyCo-Founder & Software Architect |